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Abstract 
BACKGROUND: In the clinically and genetically heterogeneous group of the hereditary 
spastic paraplegias (HSPs), mutations in the SPAST gene are most frequently found and cause 
a pure autosomal dominant form. 
OBJECTIVE: To provide the clinical and genetic characteristics of Dutch patients with HSP 
due to a SPAST mutation (SPG4). 
METHODS: SPAST mutation carriers were identified through a comprehensive national 
database search. Available medical records were reviewed. 
RESULTS: 151 mutation carriers carried 60 different changes in the SPAST gene, of which 
one was a known polymorphism and 27 were novel. Missense mutations were most frequently 
found (39%). Clinical information was available from 72 mutation carriers. Age at onset 
ranged from 1 to 63 years with a bimodal peak distribution in the first decade and above age 
30. The predominantly pure spastic paraplegia was accompanied by deep sensory 
disturbances and sphincter problems in almost 50%. An additional hand tremor was found in 
10%. Patients with missense mutations and exon deletions did not reveal a distinctive 
phenotype.  
CONCLUSIONS: Dutch SPAST mutation carriers show a broad mutation spectrum, with 27 
novel mutations in the present series. A bimodal peak distribution in age at onset was found 
and an accompanying tremor as peculiar feature of SPG4. The pathogenicity of S44L, the first 
exon 4 mutation, and a possible autosomal recessive mode of inheritance are discussed. 
 
Key words: SPAST, novel mutations, tremor, exon 4, S44L 
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Introduction 
The hereditary spastic paraplegias (HSPs) constitute a genetically and clinically 
heterogeneous group of disorders of which the main clinical feature is progressive lower limb 
spasticity due to pyramidal tract dysfunction. The cardinal signs result from a “dying back” 
degeneration of the corticospinal tracts and dorsal column, predominantly affecting axonal 
transport of the longest fibers that innervate the lower extremities.[1] Neuro-imaging of HSP 
patients can reveal spinal cord atrophy, mostly at the thoracic level.[2] In addition, corpus 
callosum atrophy (although more common in autosomal recessive HSP), atrophy of the 
cerebellum, and white matter lesions have all been found in HSP.[3,4] 
If neurological signs are limited to the lower limbs, eventually accompanied by urinary 
urgency and mildly impaired vibration sense at the ankles, HSP is classified as “pure”.[5] In 
contrast, HSP is classified as a “complicated” form if additional neurological signs are 
present, such as mental retardation, extrapyramidal signs, visual dysfunction, epilepsy, or 
systemic involvement.[5]  
HSP may be inherited as an autosomal dominant (AD), an autosomal recessive (AR) or an X-
linked disease, with more than 40 loci identified.[6] AD transmission is observed in 70 to 
80% of all HSP cases in Western countries.[7] Mutations in SPAST are responsible for about 
40% of the AD-HSP cases and cause a predominantly pure HSP.[4] Over 150 mutations of 
different types (missense, nonsense and splice mutations, deletions, and insertions) along the 
SPAST gene have been reported. SPAST is a gene encoding the spastin protein, which is a 
member of the ATP-ases Associated with various cellular Activities (AAA) family.[4] Both 
the AAA-domain and the MIT(microtubule interacting and trafficking)-domain of the SPAST 
gene play an important role. Recent studies confirmed that spastin possesses microtubule-
severing activity, necessary for axonal transport.[8]  A loss of function of spastin due to a 
SPAST mutation, could thus lead to axonal dysfunction.  
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There is a broad clinical spectrum of SPAST mutations, even within families, and the 
genotype-phenotype correlations remain largely unclear. To further expand our knowledge on 
the phenotypic and genetic spectrum of SPAST-linked HSP, we studied the mutations and 
disease characteristics of a comprehensive cohort of Dutch SPAST mutation carriers and 
found some new features. 
 
 
Methods 
Patients 
The DNA diagnostic laboratory within the Dept. of Human Genetics of the Radboud 
University Nijmegen Medical Centre (RUNMC) is the single national laboratory to provide 
SPAST mutation analysis for the Netherlands, being offered since 2000. Thus, we were able to 
identify all Dutch SPAST mutation carriers from a laboratory information system query. 
Available medical records and imaging data were reviewed. A clinicogenetic HSP-database 
was composed containing clinical information from history, with the age of onset as 
mentioned by the patient, and neurological examination, combined with the results of genetic 
testing and additional investigations (CT-MRI-EMG-laboratory-other). The study has been 
carried out in the Netherlands in accordance with the applicable rules concerning the review 
of studies by research ethics committees and informed consent. 
 
Genetic analysis: 
Mutation analysis of the SPAST gene was performed by sequencing of the coding sequences 
including flanking intronic sequences as well as multiplex ligation-dependent probe 
amplification (MLPA) assay in all patients, using the methods described previously.[9,10] 
NM_014946.3 was used as reference sequence, with nucleotide 1 corresponding to the A of 
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the start codon. If the results were indicated by multiple flanking probes within the MLPA 
test, they were considered as indicative for a true deletion. Test results were confirmed by an 
independent test according to standard procedures. Determination of pathogenicity of point 
mutations was obtained by an in silico approach using the prediction programs SIFT (Sorting 
Intolerance from Tolerance; http://sift.jcvi.org), Align GVGD (http://agvgd.iarc.fr/) and 
POLYPHEN (Polymorphism Phenotyping; http://genetics.bwh.harvard.edu/pph/).[11,12]  
 
 
Results 
From July 2000 till July 2008, mutation analysis was performed in 1386 Dutch patients with 
suspected HSP, in the presence or absence of affected family members. This yielded 151 (i.e. 
11%) positive carriers originating from 84 families. Five patients were sporadic. We had 
sufficient clinical data from 72 carriers (from 47 families) to study the phenotypic spectrum.  
 
Genotypic spectrum 
The 151 mutation carriers originating from 84 families were found to carry 60 different 
changes in the SPAST gene, one of which is a known polymorphism (p.Ser44Leu; see below 
and the discussion). Overall, we found 23 missense mutations (39%), 10 splice site mutations 
(17%), 9 small deletions (15%), 8 deletions of single or multiple exons (14%), 6 nonsense 
mutations (10%), 2 duplications (3%), and 1 insertion (2%) (Supl. table 1). Mutations 
occurred throughout the whole gene. According to the international electronic database 
(www.hgvs.org), we identified 27 novel SPAST mutations (Table 1). By MLPA analysis we 
identified 8 different large exonic deletions in the SPAST gene, 3 of which are novel. Most 
families showed private mutations. Some mutations were observed more frequently, like 
c.1174del (p.Ala392fs). All, but one, novel missense mutations are clustered in the AAA-
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domain. The other mutation is located in the MIT (microtubule interacting and trafficking) 
domain (Figure 1). 
 
Phenotypic spectrum 
The phenotype could be defined for 72 cases. Five of them were asymptomatic SPAST 
mutation carriers (according to their history) and were not included in determining the 
phenotypic spectrum, apart from the tendon reflexes (table 2). In total, 47 distinct families 
could be identified based on available family information.  
The family history of these patients revealed an autosomal dominant mode of inheritance with 
certainty in 72% of the 72 cases. Five cases were sporadic (6.9%). In one family an autosomal 
recessive mode of inheritance was observed, associated with a unique missense mutation in 
exon 14 (c.1600C>G: p.Leu534Val). The two affected siblings, who showed a pure spastic 
paraparesis, were homozygous for the mutation, while the heterozygous consanguineous 
parents were fully asymptomatic at ages of 73 and 68 years (see also the Discussion).  
 
The age of onset varied from 1 to 63 years (mean 33.4 ± SD 18.3 years), and showed a 
bimodal distribution with a first peak in the first decade and a second peak between 30 and 60 
years (figure 2).  
Most patients presented with gait difficulty (Table 2). The overall phenotype was that of a 
slowly progressive, mostly pure spastic paraparesis with only little or no arm involvement. 
Strength and tone of the upper limbs were almost always normal, but the tendon reflexes in 
the arms were brisk in 61%. Mild cerebellar ataxia of the arms was present in a few cases. 
Ataxia of gait was more common; 32% of the patients presented with a spastic ataxic gait 
and/or difficulty with tandem gait. Muscle tone of the lower limbs was increased in most 
patients (85%). Muscle strength was only mildly impaired or normal, with 80% of cases who 
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demonstrated strength of at least MRC 4. The small group with a (lower limb) muscle 
strength of less than MRC 4 showed a significant longer disease duration (mean of 24 years) 
compared to the group with a strength of at least MRC 4  (mean duration of 10 years). Brisk 
reflexes of the lower limbs were found in 95% with Babinski signs in 86% (in 72% 
bilaterally). About one third of the patients used some sort of walking aid, 15% was 
completely wheelchair bound. 
Deep sensory modalities were disturbed in almost half of the patients (47%). Vibration sense 
was predominantly impaired. Bladder disturbances, predominantly urinary urgency, were 
present in 42% of the patients, and anal sphincter disturbances in 15 %.   
Swallowing problems were mentioned by 2 patients (3%), in whom mild dysarthria was also 
noticed.  
Patients with missense mutations did not show a significant earlier age of onset (33.8 years vs. 
33.3), compared to other types of mutations. In both the <35 age group and in the >35 age 
group we observed an approximately 40% proportion of missense mutations, respectively 
38% and 43%, without a preference for the younger age of onset group. The clinical 
presentation and the age of onset of the patients with an exonic deletion was similar to those 
with loss of function mutations, i.e. missense, nonsense and splice site mutations.   
Neuro-imaging of the brain and the spinal cord was performed in 39 patients.  Eight (21%) of 
these scans showed HSP-associated abnormalities: 4 patients had atrophy of the spinal cord; 
the others had atrophy of the cerebrum (n=1), cerebellum (n=1) and a thin corpus callosum 
(n=2). Unspecific white matter lesions (WML) were seen in 4 (10%) patients, who were at 
that time aged 44 to 62 years. 
 
Complex phenotype 
  
 
 
8 
Over one fifth (22%) of the patients presented with a relatively mild complex phenotype 
(table 3), based on clinical and/or imaging features. The abnormalities were mostly minor. A 
mild tremor of the arms was present in 7/67 patients (10%). Three patients showed a postural 
tremor, three patients an intention tremor and one patient an action tremor. A more severe 
complex phenotype, based for example on the presence of mental retardation or dementia, 
was rare. 
 
Clinical data of the S44L family 
We found one family in which the known p.Ser44Leu polymorphism is segregating. No 
additional pathogenic SPAST mutation was identified. The mother was heterozygous for this 
variant and showed no signs or symptoms. The father was also heterozygous, but presented 
with sphincter problems at the age of five years. On examination, his legs were hypertonic 
with increased tendon reflexes and Babinski’s sign bilaterally. The son, who was homozygous 
for the p.Ser44Leu variant, presented with sphincter disturbances at age six, but without any 
difficulty of gait or abnormalities on examination (see also the discussion). 
 
 
Discussion 
SPAST mutations comprise by far the most frequent form of autosomal dominant spastic 
paraplegia (between 15 and 40% of AD-HSP’s).[4,13] Our cases represented 11% of all 
requests for SPAST mutation analysis, but it should be kept in mind that these requests 
emerged from an unselected cohort that included sporadic and even probably recessive 
paraplegia cases. A German study revealed 17% SPAST mutations in a comparable population 
suffering from spastic paraplegia with or without a family history.[9] 
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Here, we report a comprehensive overview of the phenotypic and genotypic spectrum of all 
identified SPAST mutation carriers in the Netherlands. Since the RUNMC is the only centre in 
the Netherlands providing SPAST mutation analysis, this overview includes all known SPAST 
carriers in the Netherlands. The identification of 151 SPAST mutation carriers results in a 
prevalence of 0.92 carriers per 100.000 in the Netherlands.  
 
Mutations 
Of the 60 different changes in the SPAST gene identified, one was a previously described non-
pathogenic polymorphism (p.Ser44Leu), 59 were true mutations. We also confirmed the 
existence of exonic deletions, which is consistent with findings recently reported.[13,14] In 
our cohort, missense mutations were the most frequent (39%), followed by splice site 
mutations (17%) and small deletions (15%). Comparable figures were found in two other 
studies.[15,16]  
The most frequent mutation was a previously described mutation (c.1174del), in the AAA 
(ATP-ases Associated with various cellular Activities) domain.[16] This deletion results in a 
frameshift after the alanine at position 392 and was found in 5 out of 84 families (6%).   
A novel finding is the deletion of exon 4 in one family suffering from a well-defined spastic 
paraplegia. The pathogenicity of this mutation is not certain, as SPAST is alternatively spliced. 
Exon 4 is spliced out in one transcript, coding for a slightly shortened isoform 
(NM_199436.1). The transcript without exon 4 is still in frame, and it is not known what the 
functional consequences are of this deletion.  
 
Mode of inheritance 
In 7/84 (8%) families the mode of inheritance was uncertain, but probably best fits with 
incomplete penetrance of an autosomal dominant trait, or incomplete clinical assessment of 
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the parents. Incomplete penetrance and reduced or delayed expression, which is depending on 
the age at the time of examination, have been described before in a relatively high proportion 
(24.1%) of SPAST mutation carriers.[17] In this Irish study even a case of true non-penetrance 
was observed.  
Five cases seemed sporadic (6.9%) which is due to a de novo mutation, incomplete 
penetrance, somatic mosaicism, non-paternity, or incomplete clinical assessment of the 
parents. De novo mutations have been found in 6% of cases in an Italian study and in 12% in 
a French study.[18,19] As we have not systematically investigated all family members, we 
cannot further comment on our sporadic cases. 
One family presented with a (pseudo-)recessive inheritance. Both parents, who were 
consanguineous, had a heterozygous missense mutation, c.1600C>G (p.Leu534Val), without 
signs or symptoms at ages 73 and 68 years, respectively. Their two children, homozygous 
carriers of the mutation, presented with a pure spastic paraparesis, both with an onset at age 
39 years. Both patients were tested negative for SPG7. There are several explanations for 
these findings. First, this mutation (c.1600C>G, p.Leu534Val) may only be pathogenic in a 
homozygous state (thus representing a recessive disease). Second, the opposite SPAST allele 
may in fact be (partly) deleted. The allele carrying the c.1600C>G mutation would thus 
appear to be homozygous after sequencing. This, however, is very unlikely as both parents are 
carrier of the mutation. The third explanation is that the mutation is a non-pathogenic 
polymorphism. In that case, the diagnosis cannot be confirmed genetically. However, a 
different heterozygous missense mutation affecting the same amino acid residue, c.1601T>C 
(previous nomenclature in literature: c.1726T>C); p.Leu534Pro, has been described causing 
an autosomal dominant pure HSP.[20] The leucine to valine change (both nonpolar, 
hydrophobic amino acids) is less dramatic than the leucine to proline change (a moderately 
polar, negatively charged amino acid with the additional capacity to form a hydrogen bond). 
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This could well explain the fact that L534P acts in a dominant way, whereas L534V only has 
a pathogenic effect when present in a homozygous state. The p.Leu534Val concerns a 
conservative change of a strongly conserved amino acid. Due to the high conservation, the 
change is predicted to affect protein function by online prediction tools SIFT and Align 
GVGD (refs 1, 2). Also the fact that p.Leu534Val is located in the AAA domain, may cause it 
to be pathogenic.[11,12]  
 
S44L 
S44L (p.Ser44Leu) is a relatively rare, but well-described non-pathogenic polymorphism. In a 
North American control population, the L44 allele was found in 0.6% of individuals examined 
and in a British control population even in 3.1%.[15,21] However, a role as a phenotypic 
modifier is also attributed to S44L previously.[15,21] 
One family in which this polymorphism is segregating was found in our study. The father’s 
disease, which is compatible with an early onset spastic paraplegia, may be caused by an as of 
yet unidentified mutation in one of the genes underlying paraplegia, suggesting a role for 
p.Ser44Leu as a genetic modifier. This may include an unidentified mutation in a regulatory 
or intronic region of SPAST. An English severely affected child with compound 
heterozygosity for p.Pro361Leu and p.Ser44Leu in the SPAST gene supports this 
hypothesis.[22]  Urinary urgency and frequency together with hyperreflexia were the main 
features in this family, comparable to our case. In case of co-occurrence of another SPAST 
mutation, S44L would act via a gain of function mechanism and worsen a primary ‘loss of 
function’ effect caused by a different loss of function mutation occurring in trans.[23] An 
imbalance between short and long isoforms could be responsible for a mild pathogen effect of 
an isolated S44L mutation.[23] Another explanation could be that p.Ser44Leu shows a high 
variability in phenotypic expression, rather than being a genetic modifier. Two Norwegian 
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families with HSP and a p.Ser44Leu polymorphism were described; both without an identified 
pathological SPAST mutation.[24] Some of the family members were homozygous, others 
heterozygous for the polymorphism, associated with or without clinical symptoms. 
Development of a more severe disease due to a homozygous mutation of S44L, as in the son 
in our case, has been suggested before.[16] 
Thus, rather than being completely non-pathogenic and innocent, it should be suspected that 
p.Ser44Leu, under specific conditions, may cause a mild HSP phenotype, with a more severe 
phenotype, when combined with a classical SPAST mutation, or in a homozygous mutation. 
 
Phenotype 
The phenotype of gait difficulty due to a slowly progressive pure spastic paraparesis with 
little or no arm involvement, accompanied by impairment of deep sensory modalities and 
sphincter problems, is fully consistent with the phenotype as reported in the literature.[15,16] 
Compared to almost 42% bladder disturbances and 14.5% anal sphincter disturbances in our 
cohort, urinary urgency was only found in 21% of the British cases.[15] This difference may 
be caused by the intensity of questioning rather than by a true difference. Also the proportion 
of patients who were wheelchair bound in our study (15%), is comparable with the 17% 
reported previously.[4] In contrast, swallowing problems and dysarthria, which were present 
in 2 of our 67 symptomatic patients (3%), have not been reported previously.  
One-fifth of our patients had a, mostly mild, complex phenotype, with additional signs or 
symptoms not attributable to the pyramidal tract or dorsal columns. Hand tremor was 
observed in 10% of SPAST patients. A literature search did not reveal any recent reports of 
tremor in SPAST patients, but might have been overlooked clinically. In a family description 
from 1963 a ‘slight intention tremor’ in four patients was mentioned as an atypical feature of 
AD-HSP.[25] The other additional neurological symptoms or signs found in a part of our 
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cohort, such as neuropathy, epilepsy, mental retardation, cerebellar atrophy and thinning of 
the corpus callosum have previously been described in SPAST patients.[6] A mild form of 
dementia, which has been described as an associated symptom in SPAST patients, was 
however only found in one of our SPAST patients.[26] Based on neuropsychological testing, 
CSF findings and brain MRI in our patient, this cortical dementia could be either SPAST-
related or Alzheimer’s dementia. 
 
The mean age of onset in our cohort was 33.4 ± 18.3 years, ranging from 1 to 63 years, with a 
bimodal distribution showing a peak in the first decade and a second peak in the 4th till 6th 
decade. A mean age of onset of 29-34 years with a comparable broad range was found in 
previous studies.[15,16,17] However, a clear bimodal distribution, as we describe, was not 
found in these European studies and we clearly found more patients with an age of onset in 
the 1st and 6th decade (both 19%), compared to other reports. The challenge here is to assess 
the exact age of onset. Currently, this is estimated by careful history taking, but this method 
may yield systematic error as many patients probably go through an initial phase in which 
they do not yet experience symptoms, while hyperreflexia could already be present. 
 
In the group with exonic deletions a similar phenotype was found in our study, as in the group 
with loss of function mutations caused by a base pair substitution or a small deletion or 
insertion, as previously has been described.[13,14] In contrast to other studies, our results do 
not confirm the recently proposed hypothesis of an earlier onset of the disease when caused 
by a missense mutation in the AAA domain.[10] 
 
Spinal cord atrophy, as was found in 4 of our patients, has been described in SPAST 
patients.[2] In the same study, MRI of the brain was normal and the thickness of the corpus 
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callosum did not differ from healthy controls.[2] Another study also showed atrophy of the 
midthoracic cord, and in this study the corpus callosum was indeed significantly smaller in 
patients in comparison to healthy controls.[3] However, in that study not all patients were 
tested for SPAST mutations, but were merely diagnosed with pure HSP. On the contrary, 
another study states that a thin corpus callosum is not associated with SPAST-linked HSP.[27] 
We found 2 patients with a thin corpus callosum, supporting a possible association with 
SPAST.  
Four patients showed so-called unspecific WML on brain-MRI. It is questionable whether this 
finding is of any value, i.e. linked to HSP. It may be related to age, as the youngest patient 
with WML was 44 years old. The literature is also ambiguous. In some, mostly older papers, 
WML are indeed linked to HSP.[28,29] Others suggest that WML are not more common in 
HSP patients then in controls.[30] No age-matched comparisons have yet been conducted. 
 
 
Conclusion  
Dutch patients with HSP due to a SPAST mutation show a broad mutation spectrum, with 59 
different mutations identified of which 27 are novel. Clinically, a predominantly pure spastic 
paraparesis was observed, with a wide range of age at onset, consistent with other reports of 
large populations of SPAST patients in Western countries. 
Interestingly, a distinct bimodal peak distribution of age at onset, at the first decade and 
between 30 and 60 years of age, was found in the Dutch population. Compared to previous 
studies, an age at onset before 10 and after 50 years was relatively more frequent. Although 
urinary urgency is frequently described in the literature, bladder and anal sphincter 
disturbances were more common observed in this study and might have been underestimated. 
As a complicating feature, a tremor was found in almost 10% of the patients, a feature which 
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needs more detailed investigation in future studies. The same applies to a possible autosomal 
recessive mode of inheritance of the missense mutation in exon 14 (c.1600C>G: 
p.Leu534Val), the role of the p.Ser44 Leu variant and of exon 4 mutations.  
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Figure 1: Schematic figure showing the structural domains of SPAST. Indicated are all 
missense mutations identified in this study. Open circles indicate known mutations, closed 
circles indicate novel mutations. All but one novel missense mutation was detected in the 
AAA domain; the other mutation was detected in the MIT domain.  
 
 
Figure 2: distribution (in %) of the age at onset in 67 HSP patients with SPAST mutations, 
with a peak of 19% with an age of onset before 10 years and a peak of 25% with an age of 
onset between 40 and 49 years.  
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No. Exon/intron 
cDNA (nucleotide 
change) 
Amino acid 
change 
Mutation 
type 
Effect 
1 
 
 
Ex 1 c.153C>G p.Tyr51X Nonsense Premature termination 
codon (PTC) 
2 
 
 
Ex 1 c.155_156dup p.Phe53fs Duplication Frameshift leading to 
downstream PTC 
3 
 
Ex 1 c.310del p.Ala104fs Deletion Frameshift leading to PTC 
4 Ex 1 c.328_340del 
 
p.Gly110fs 
 
Deletion Frameshift leading to PTC 
5 
 
 
 
Ex 2 c.484G>A p.Val162Ile Missense Conservative change in 
residue conserved up to 
frog; MIT domain 
6 Ex 5 
 
c.790del p.His264fs Deletion Frameshift leading to PTC 
7 
 
Ex 7 c.1061T>A p.Leu354X Nonsense PTC 
8 
 
 
 
Ex 7 c.1066G>A p.Glu356Lys Missense Non-conservative change 
of a strong conserved 
amino acid in the AAA-
cassette 
9 Ex 7 
 
c.1069del p.Ile357fs Deletion Frameshift leading to PTC 
10 
 
 
 
Ex 7 c.1093C>T p.Pro365Ser Missense Mutation in the AAA-
cassette that influences the 
correct splicing of the gene 
11 
 
 
 
 
Ex 8 c.1144G>C p.Gly382Arg Missense Non-conservative change 
of a very strong conserved 
amino acid in the AAA-
cassette 
12 In 8 
 
c.1174-2A>C p.? Splice site Influences the splice 
acceptor of exon 9. A skip 
is very likely.  
13 
 
 
 
Ex 9 c.1220G>T p.Ser407Ile Missense Non-conservative change 
of a conserved residue in 
the conserved AAA-
cassette 
14 
 
 
In 9 c.1245+1G>C p.? Splice site Influences the splice donor 
site of exon 9. A skip is 
very likely. 
15 Ex 10 
 
c.1266G>C p.Leu422Phe Missense Mutation of a conserved 
residue in the conserved 
AAA-cassette 
16 
 
 
 
Ex 11 c.1334G>A p.Ser445Asn Missense Mutation of a conserved 
residue in the conserved 
AAA-cassette 
17 Ex 11 
 
c.1378C>A p.Arg460Ser Missense Mutation of a conserved 
residue in the conserved 
AAA-cassette 
18 
 
 
 
Ex 12 c.1444G>C p.Val482Leu Missense Mutation of a conserved 
residue in the conserved 
AAA-cassette 
19 Ex 13 c.1500_1501insT p.Ile501fs Insertion Frameshift leading to PTC 
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20 
 
 
Ex 13 c.1534_1536del p.Glu512del Deletion Influences the function of 
the AAA-cassette domain 
21 
 
 
 
Ex 14 c.1600C>G p.Leu534Val Missense Mutation of a conserved 
residue in the conserved 
AAA-cassette 
22 
 
 
Ex 15 c.1628dup p.Tyr544fs Duplication Frameshift leading to PTC 
23 
 
 
 
Ex 15 c.1685G>C p.Arg562Pro Missense Mutation of a conserved 
residue in the conserved 
AAA-cassette 
24 Ex 17 
 
c.1817del p.Arg606fs Deletion Frameshift leading to PTC 
25 
 
 
 
Ex 3-17 c.503-?_1851+?del Unknown Exon 
deletion 
Deletion of major part of 
the SPAST gene  leads to 
an unstable transcript 
26 
 
 
Ex 4 c.587-?_682+?del Unknown Exon 
deletion 
In frame deletion of 32 
amino acid residues 
27 Ex 14-17 c.1537-
?_1851+?del 
Unknown Exon 
deletion 
Deletion of 3’ part of the 
SPAST gene will lead to a 
short and unstable 
transcript 
 
Table 1: List of 27 novel mutations identified in the SPAST gene in our HSP cohort 
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Characteristic 
 
Characteristic 
 
Men : women  3:2 Atrophy lower limb (%) 5/43 (12%) 
Mean age at onset (years) (n=67) 
33.4 ± SD 18.3  
(range 1 to 67 years) Spastic gait (%) 47/66 (71%) 
Mean age at examination (years) 
46.2 ± SD 16.7 
(range 1 to 72 years )    Walking aid (stick or wheelchair) (%) 19/59  (32%) 
Family history (%) Positive 67/72 (93%) Wheelchair bound completely (%) 9/59 (15%)   
Mental retardation/deterioration (%) 2/67 (3%)  Reflexes upper limbs  
Abnormalities of cranial nerves/brainstem (%) 6/62 (10%)      Normal 25/66 (38%) 
     Eye movements 1/62 (2%)      Brisk 40/66 (61%) 
     Optic atrophy 3/49 (6%)      Decreased 1/66 (2%) 
     Speech 4/62 (7%) Reflexes lower limbs  
     Swallowing 2/61 (3%)      Normal 3/72 (4%) 
Upper limb weakness (%)       Brisk 68/72 (95%) 
     Absent (MRC 5) 57/60 (95%)      Decreased  1/72 (1%) 
     Mild (MRC 4-5) 3/66 (5%) Babinski sign  61/71 (86%) 
Lower limb weakness (%)       Bilateral 51/71 (72%) 
     Absent (MRC 5) 29/62 (47%)      Unilateral 10/71 (14%) 
     Mild (MRC 4) 21/62 (34%) Ataxia (%)  
     Moderate (MRC 3) 6/62 (10%)      Upper limb  8/52 (15%) 
Tone upper limb (%)        Lower limb  8/45 (18%) 
     Normotonia 38/42 (90%)      Gait  15/47 (32%)  
     Hypertonia 4/42 (10%) Superficial sensory modalities 6/66 (9%) 
Tone lower limb (%)  Deep sensory modalities 31/66 (47%) 
     Hypotonia 1/54 (2%) Sphincter disturbances (%)  28/62 (45%) 
     Normotonia 7/54 (13%)      Bladder (mostly urinary urgency) 26/62 (42%) 
     Hypertonia 46/54 (85%)      Anal     9/62 (15%) 
 
Table 2: phenotypic characteristics in 72 SPAST mutation carriers, among which 5 were 
asymptomatic according to history. MRC: Medical Research Council scale. 
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 Number of patients n=67 
Pure 
52 (77.6 %) 
Complicated 
15 (22.4 %) 
∙ tremor 
7 (10.4 %) 
∙ optic  atrophy  
2 (3.0 %) 
∙ polyneuropathy 
2 (3.0 %) 
∙ thin corpus callosum 
2 (3.0 %) 
∙ mental retardation 
1 (1.5 %) 
∙ dementia 
1 (1.5%) 
∙ epilepsy   
1 (1.5 %) 
∙ cerebellar atrophy 
1 (1.5 %) 
 
Table 3: Pure versus complex phenotype of the 67 SPAST patients based on clinical and/or 
imaging features.   
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No Exon/ 
intron 
cDNA 
(nucleotide 
change) 
Amino acid 
change 
Mutation type Ref. 
1 
 
Ex 1 c.131C>T p. Ser44Leu Missense 
(polymorphism) 
Lindsey (2000) J Med 
Genet 37, 759 
2 
 
Ex 1 c.134C>A p. Pro45Gln Missense Svenson (2004) 
Neurogenetics 5, 157 
3 
 
Ex 1 c.153C>G p.Tyr51X Nonsense novel 
4 
 
Ex 1 c.155_156dup p.Phe53fs Duplication novel 
5 
 
Ex 1 c.310del p.Ala104fs Deletion novel 
6 Ex 1 c.328_340del 
 
p.Gly110fs 
 
Deletion novel 
7 
 
Ex 1 c.412A>T p.Lys138X Nonsense Vergouwen (2008) J 
Neurol 255, 303 
8 
 
Ex 2 c.484G>A p.Val162Ile Missense novel 
9 
 
In 3 c.586+9_586+1
2del 
 Deletion Higgins (2001) 
Neurology 56, 1482 
10 
 
Ex 5 c.790del p.His264fs Deletion novel 
11 
 
In 5 c.871-1G>A p.? Splice mutation Shoukier (2009) Eur J 
Hum Genet 17, 187 
12 
 
 
In 6 c.1004+2T>G p.? Splice mutation Fonknechten (2000) 
Hum Mol Genet 9, 637 
13 
 
 
In 6 c.1004+5G>T p.? Splice mutation Loureiro (2009) Acta 
Neurol Scand 119, 113 
14 In 6 
 
c.1005-2A>G p.? Splice mutation McDermott (2006) 
Neurology 67, 45 
15 
 
Ex 7 c.1048G>C p.Ala350Pro Missense Brugman (2005) Ann 
Neurol 58, 865 
16 
 
Ex 7 c.1061T>A p.Leu354X Nonsense novel 
17 
 
Ex 7 c.1066G>A p.Glu356Lys Missense novel 
18 
 
Ex 7 c.1069del p.Ile357fs Deletion novel 
19 
 
Ex 7 c.1082C>T p.Pro361Leu Missense Chinnery (2004) 
Neurology 63, 710 
20 
 
Ex 7 c.1093C>T p.Pro365Ser Missense novel 
21 
 
Ex 8 c.1144G>C p.Gly382Arg Missense novel 
22 
 
In 8 c.1174-2A>C p.? Splice site novel 
23 
 
Ex 9 c.1174del p.Ala392fs Deletion Fonknechten (2000) 
Hum Mol Genet 9, 637 
24 
 
Ex 9 c.1196C>T p.Ser399Leu Missense Meijer (2002) Arch 
Neurol 59, 281 
25 
 
Ex 9 c.1216A>G p.Ile406Val Missense Schickel (2006) 
Neurology 66, 421 
26 
 
Ex 9 c.1220G>T p.Ser407Ile Missense novel 
27 
 
Ex 9 c.1245del p.Tyr415X Deletion Shoukier (2009) Eur J 
Hum Genet 17, 187 
28 In 9 c.1245+1G>C p.? Splice site novel 
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29 
 
In 9 c.1245+1G>A p.? Splice site Svenson (2001) Am J 
Hum Genet 68, 1077 
30 
 
Ex 10 c.1266G>C p.Leu422Phe Missense novel 
31 
 
Ex 10 c.1276C>G p. Leu426Val Missense Fonknechten (2000) 
Hum Mol Genet 9, 637 
32 
 
Ex 11 c.1324G>T p. Glu442X Nonsense Brugman (2005) Ann 
Neurol 58, 865 
33 
 
Ex 11 c.1334G>A p.Ser445Asn Missense novel 
34 
 
Ex 11 c.1378C>A p.Arg460Ser Missense novel 
35 
 
Ex 11 c.1378C>T p.Arg460Cys Missense Falco (2004) 
Neuromuscul Disord 
14, 750 
36 
 
Ex 12 c.1444G>C p.Val482Leu Missense novel 
37  
 
Ex 12 c.1466C>T p.Pro489Leu Missense Meijer (2002) Arch 
Neurol 59, 281 
38 In 12 c.1493+2_1493
+5del 
p.? Splice site Buerger (2000) Eur J 
Hum Genetics 
39 
 
Ex 13 c.1496G>A p.Arg499His Missense Park (2005) Arch 
Neurol 62, 1118 
40 
 
Ex 13 c.1500_1501ins
T 
p.Ile501fs Insertion novel 
41 
 
Ex 13 c.1534_1536del p.Glu512del Deletion novel 
42 
 
Ex 14 c.1600C>G p.Leu534Val Missense novel 
43 
 
Ex 15 c.1625A>G p.Asp542Gly Missense Brugman (2005) Ann 
Neurol 58, 865 
44 
 
Ex 15 c.1628dup p.Tyr544fs Duplication novel 
45 
 
Ex 15 c.1685G>A p.Arg562Gln Missense Meijer (2002) Arch 
Neurol 59, 281 
46 
 
Ex 15 c.1685G>C p.Arg562Pro Missense novel 
47 
 
In 15 c.1688-2A>G p.? Splice mutation Hazan (1999) Nat 
Genet 23, 296 
48 In 16 c.1729-2A>T p.? Splice mutation Ivanova (2006) Clin 
Genet 70, 490 
49 
 
Ex 17 c.1735A>C p.Asn579His Missense Brugman (2005) Ann 
Neurol 58, 865 
50 
 
Ex 17 c.1741C>T p. Arg581X Nonsense Patrono (2005) Hum 
Mutat 25, 506 
51 
 
Ex 17 c.1817del p.Arg606fs Deletion novel 
52 
 
Ex 17 c.1820G>A p.Trp607X Nonsense Patrono (2005) Hum 
Mutat 25, 506 
53 
 
Ex 1 c.1-?_415+?del Unknown Exon deletion Depienne (2007) J 
Med Genet 44, 281 
54 Ex 2-17 
 
c.416-
?_1851+?del 
Unknown Exon deletion Erichsen (2007) Eur J 
Neurol 14, 809 
55 
 
Ex 3-17 c.503-
?_1851+?del 
Unknown Exon deletion novel 
56 
 
Ex 4 c.587-
?_682+?del 
Unknown Exon deletion novel 
57 Ex 8+9 c.1099- Unknown Exon deletion Svenstrup (2009) J 
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 ?_1245+?del Neurol Sci 284, 90 
58 
 
Ex 9 c.1174-
?_1245+?del 
Unknown Exon deletion Depienne (2007) J 
Med Genet 44, 281 
      
59 Ex 14-
17 
c.1537-
?_1851+?del 
Unknown Exon deletion novel 
60 Ex 17 c.1729-
?_1851+?del 
Unknown Exon deletion Beetz (2007) Hum 
Mutat 28, 739 
 
Supplementary table 1. All mutations found in the Dutch cohort of 151 SPAST mutation 
carriers, including the 27 novel mutations found. 
 


